Enhancing Modulation Effects of Baduanjin Through Neuromodulation for Knee OA

Sponsor
Massachusetts General Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05839535
Collaborator
(none)
140
4
60

Study Details

Study Description

Brief Summary

This study will combine brain imaging and neuromodulation tools to investigate the underlying neurobiological mechanisms of exercises. The findings will enhance our understanding of the mechanisms underlying mind-body exercise and facilitate the development of new pain management approaches.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: BDJ
  • Device: tDCS
  • Device: sham tDCS
  • Other: exercise
Phase 2

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Enhancing Modulation Effects of Baduanjin Through Non-invasive Neuromodulation for Knee Osteoarthritis
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Mar 30, 2028
Anticipated Study Completion Date :
Aug 31, 2028

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: BDJ + real tDCS

Behavioral: BDJ
BDJ is a mind-body intervention

Device: tDCS
tDCS is a brain stimulation method.

Active Comparator: Exercise + real tDCS

Device: tDCS
tDCS is a brain stimulation method.

Other: exercise
exercise including stretching and other activities.

Active Comparator: BDJ + sham tDCS

Behavioral: BDJ
BDJ is a mind-body intervention

Device: sham tDCS
sham tDCS

Active Comparator: Exercise + sham tDCS

Device: sham tDCS
sham tDCS

Other: exercise
exercise including stretching and other activities.

Outcome Measures

Primary Outcome Measures

  1. Change on functional connectivity of the bilateral M1. [Baseline, post-treatment (12 weeks)]

    Resting state connections between the primary motor area (M1) and other brain regions

Secondary Outcome Measures

  1. Change on cerebral blood flow [Baseline, post-treatment (12 weeks)]

    Cerebral blood flow will be measured using arterial spin labeling (ASL)

  2. Change on M1 corticospinal excitability and cortico-cortical excitability [Baseline, post-treatment (12 weeks)]

    M1 corticospinal excitability will be measured using motor threshold, motor evoked potential, short-interval intracortical inhibition (SICI) and intracortical facilitation (ICF).

  3. Change on brain gray matter volume [Baseline, post-treatment (12 weeks)]

    Voxel-based morphometry (VBM) analysis will be performed to investigate gray matter volume changes.

  4. Change on Knee Injury and Osteoarthritis Outcome Score (KOOS) [Baseline, post-treatment (12 weeks), follow-up (24 weeks)]

    The KOOS is a 35-item self-administered survey of pain and function in knee OA patients.

  5. Change on Patient-Reported Outcomes Measurement Information System (PROMIS)-29 [Baseline, post-treatment (12 weeks), follow-up (24 weeks)]

    We will use PROMIS-29 to assess pain, function, depression, anxiety, and sleep in the past 7 days.

  6. change on Beck's Depression Inventory (BDI-II) [Baseline, post-treatment (12 weeks), follow-up (24 weeks)]

    BDI-II is designed for individuals aged 13 and over and is composed of items relating to symptoms of depression.

  7. Change on Pain Catastrophizing Scale (PCS) [Baseline, post-treatment (12 weeks), follow-up (24 weeks)]

    PCS is a 15-item questionnaire used to characterize an individual's tendency to magnify the threat value of a pain experience and to feel helpless in the presence of pain.

  8. Change on Quantitative Sensory Testing (QST) [Baseline, post-treatment (12 weeks), follow-up (24 weeks)]

    Pressure pain thresholds will be assessed 3 times using a Somedic digital pressure algometer. Contact heat stimuli will be delivered using a PATHWAY CHEPS (Contact Heat-Evoked Potential Stimulator, Medoc Advanced Medical Systems).

  9. Change on 6-Minute Walk Test [Baseline, post-treatment (12 weeks), follow-up (24 weeks)]

    The 6-Minute Walk Test is a self-paced endurance test that assesses walking ability and endurance and includes standardized encouragement that increase tolerability in elders and those with physical impairment.

Eligibility Criteria

Criteria

Ages Eligible for Study:
45 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Volunteers 45-75 years of age

  • Meet the Classification Criteria of the American College of Rheumatology for osteoarthritis of the right and/or left knee for at least the past 3 months [292];

  • Physically able to participate in the BDJ and stretching control education programs

  • Willing to complete the 12-week study

  • Can participate in MRI scan

  • Ability to read and understand English; English can be a second language provided that the patient feels he or she can understand all the questions used in the assessment measures

Exclusion Criteria:
  • Has performed BDJ, Tai Chi, Yoga, other mind-body intervention, physical therapy, or routine exercise (running, cycling, etc.) regularly in the past year

  • Serious medical conditions limiting ability of patient to participate in the study, such as symptomatic cardiovascular disease, symptomatic pulmonary disease requiring supplemental oxygen, uncontrolled metabolic diseases, severe renal and liver disease

  • Has had intra-articular steroid injections or reconstructive surgery in the prior 3 months on the affected knee; any intra-articular hyaluronic acid injections in the previous 6 months

  • Patient Mini-Mental Status Examination score below 24 [293]

  • Unable to walk without a cane or other assistive device

  • The intent to undergo surgery during the time of involvement in the study

  • Plan to permanently relocate from the region during the trial period

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Massachusetts General Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jian Kong, Principal investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT05839535
Other Study ID Numbers:
  • 2023P000908
First Posted:
May 3, 2023
Last Update Posted:
May 3, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 3, 2023